Yakovleva E V, Surin V L, Selivanova D S, Sergeeva A M, Gonсharova M V, Demidova E Yu, Soboleva N P, Makhinya S A, Dezhenkova A V, Likhacheva E A, Zozulya N I
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
Ter Arkh. 2016;88(12):120-125. doi: 10.17116/terarkh20168812120-125.
Afibrinogenemia is a rare congenital coagulopathy that leads to life-threatening bleeding. In afibrinogenemia, plasma fibrinogen levels are less than 0.1 g/L. The clinical manifestations of the disease can be both bleeding and thromboses of different localizations, which is determined by the multifunctional role of fibrinogen in hemostasis. The described cases demonstrate different clinical phenotypes of the disease. In both cases the diagnosis was confirmed by genetic examinations that revealed homozygous mutations in the fibrinogen A genes. The nature of the mutations assumes consanguineous marriages, as confirmed by the results of a genealogical analysis. Fibrinogen preparations are promising in treating afibrinogenemia in Russia.
无纤维蛋白原血症是一种罕见的先天性凝血病,可导致危及生命的出血。在无纤维蛋白原血症中,血浆纤维蛋白原水平低于0.1 g/L。该疾病的临床表现既可以是出血,也可以是不同部位的血栓形成,这取决于纤维蛋白原在止血中的多功能作用。所描述的病例展示了该疾病的不同临床表型。在这两个病例中,基因检查均证实了诊断,该检查揭示了纤维蛋白原A基因中的纯合突变。正如系谱分析结果所证实的,突变的性质表明存在近亲结婚情况。在俄罗斯,纤维蛋白原制剂在治疗无纤维蛋白原血症方面很有前景。